Novel prostate acid phosphatase-based peptide vaccination strategy induces antigen-specific T-cell responses and limits tumour growth in mice

European Journal of Immunology

Volumn 44, Issue 4, 2014, Pages 994-1004

  Saif, Jaimy M S ^a   Vadakekolathu, Jayakumar ^a   Rane, Shraddha S ^a   Mcdonald, Danielle ^a   Ahmad, Murrium ^a   Mathieu, Morgan ^a   Pockley, A Graham ^a   Durrant, Lindy ^b   Metheringham, Rachael ^b   Rees, Robert C ^a   Mcardle, Stephanie E B ^a  

^a NOTTINGHAM TRENT UNIVERSITY   (United Kingdom)

^b Oxford Science Park   (United Kingdom)

Author keywords

Immunotherapy; Prostate acid phosphatase; Prostate cancer; Tumour infiltrating lymphocyte; Vaccine

Indexed keywords

ACID PHOSPHATASE PROSTATE ISOENZYME; CANCER VACCINE; COMPLEMENTARY DNA; EPITOPE; GAMMA INTERFERON; PAP 114 128; PAP 115 123; PEPTIDE VACCINE; PROSTATE SPECIFIC ANTIGEN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN SPECIFICITY; ARTICLE; CANCER IMMUNIZATION; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOTOXICITY; DNA VECTOR; EX VIVO STUDY; GENE GUN; IMMUNOGENICITY; IN VITRO STUDY; LYMPHOCYTIC INFILTRATION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; SPLEEN CELL; TUMOR ASSOCIATED LEUKOCYTE; TUMOR GROWTH; VACCINATION;

IMMUNOTHERAPY; PROSTATE ACID PHOSPHATASE; PROSTATE CANCER; TUMOUR-INFILTRATING LYMPHOCYTE; VACCINE;

ACID PHOSPHATASE; ADENOCARCINOMA; AMINO ACID SEQUENCE; ANIMALS; ANTIGENS, NEOPLASM; CANCER VACCINES; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; EPITOPES, T-LYMPHOCYTE; FLOW CYTOMETRY; HUMANS; INTERFERON-GAMMA; MALE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; PEPTIDES; PROSTATE; PROSTATIC NEOPLASMS; T-LYMPHOCYTES; VACCINATION; VACCINES, SUBUNIT;

EID: 84897989921     PISSN: 00142980     EISSN: 15214141     Source Type: Journal    
DOI: 10.1002/eji.201343863     Document Type: Article

References (31)

1. Boyle, P. and Ferlay, J., Cancer incidence and mortality in Europe, 2004. Ann. Oncol. 2005. 16: 481-488.
2. Siegel, R., Naishadham, D. and Jemal, A., Cancer statistics. Ca. Cancer J. Clin. 2013. 63: 11-30.
3. Snyder, A., Tepper, J. E. and Slovin, S. F., Perspectives on immunotherapy in prostate cancer and solid tumors: where is the future? Semin. Oncol. 2013. 40: 347-360.
4. O'Keefe, D. S., Bacich, D. J. and Heston, W. D., Comparative analysis of prostate-specific membrane antigen [PSMA] versus a prostate-specific membrane antigen-like gene. Prostate 2004. 58: 200-210.
5. Cunha, A. C., Weigle, B., Kiessling, A., Bachmann, M. and Rieber, E. P., Tissue-specificity of prostate specific antigens: comparative analysis of transcript levels in prostate and non-prostatic tissues. Cancer Lett. 2006. 236: 229-238.
6. Gupta, S., Carballido, E. and Fishman, M., Sipuleucel-T for therapy of asymptomatic or minimally symptomatic, castrate-refractory prostate cancer: an update and perspective among other treatments. OncoTargets Therapy 2011. 4: 79-96.
7. Speetjens, F. M., Kuppen, P. J., Welters, M. J., Essahsah, F., Voet van den Brink, A. M., Lantrua, M. G., Valentijn, A. R. et al., Induction of p53-specific immunity by a p53 synthetic long peptide vaccine in patients treated for metastatic colorectal cancer. Clin. Cancer Res. 2009. 15: 1086-1095.
8. Durrant, L. G., Pudney, V. A. and Spendlove, I., Using monoclonal antibodies to stimulate antitumor cellular immunity. Exp. Rev. Vaccines 2011. 10: 1093-1106.
9. Pajot, A., Michel, M. L., Fazilleau, N., Pancre, V., Auriault, C., Ojcius, D. M., Lemonnier, F. A. et al., A mouse model of human adaptive immune functions: HLA-A2.1-/HLA-DR1-transgenic H-2 class I-/class II-knockout mice. Eur. J. Immunol. 2004. 34: 3060-3069.
10. Pere, H., Montier, Y., Bayry, J., Quintin-Colonna, F., Merillon, N., Dransart, E., Badoual, C. et al., A CCR4 antagonist combined with vaccines induces antigen-specific CD8+ T cells and tumor immunity against self antigens. Blood 2011. 118: 4853-4862.
11. Burch, P. A., Croghan, G. A., Gastineau, D. A., Jones, L. A., Kaur, J. S., Kylstra, J. W., Richardson, R. L. et al., Immunotherapy [APC8015, Provenge] targeting prostatic acid phosphatase can induce durable remission of metastatic androgen-independent prostate cancer: a Phase 2 trial. Prostate. 2004. 60: 197-204.
12. McNeel, D. G., Dunphy, E. J., Davies, J. G., Frye, T. P., Johnson, L. E., Staab, M. J., Horvath, D. L. et al., Safety and immunological efficacy of a DNA vaccine encoding prostatic acid phosphatase in patients with stage D0 prostate cancer. J. Clin. Oncol. 2009. 27: 4047-4054.
13. Wang, Y., Harada, M., Yano, H., Ogasawara, S., Takedatstu, H., Arima, Y., Matsueda, S. et al., Prostatic acid phosphatase as a target molecule in specific immunotherapy for patients with nonprostate adenocarcinoma. J. Immunother. 2005. 28: 535-541.
14. Zlotocha, S., Staab, M. J., Horvath, D., Straus, J., Dobratz, J., Oliver, K., Wasielewski, S. et al., A phase I study of a DNA vaccine targeting prostatic acid phosphatase in patients with stage D0 prostate cancer. Clin. Genitourin. Cancer 2005. 4: 215-218.
15. Klyushnenkova, E. N., Link, J., Oberle, W. T., Kodak, J., Rich, C., Vandenbark, A. A., Alexander, R. B., Identification of HLA-DRB1*1501-restricted T-cell epitopes from prostate-specific antigen. Clin. Cancer Res. 2005. 11: 2853-2861.
16. Chauvin, J. M., Larrieu, P., Sarrabayrouse, G., Prevost-Blondel, A., Lengagne, R., Desfrancois, J., Labarrière, N. et al., HLA anchor optimization of the melan-A-HLA-A2 epitope within a long peptide is required for efficient cross-priming of human tumor-reactive T cells. J. Immunol. 2012. 188: 2102-2110.
17. Melief, C. J. M. and van der Burg, S. H., Immunotherapy of established [pre] malignant disease by synthetic long peptide vaccines. Nat. Rev. Cancer 2008. 8: 351-360.
18. Bellone, M., Iezzi, G., Imro, M. A. and Protti, M. P., Cancer immunotherapy: synthetic and natural peptides in the balance. Immunol. Today 1999. 20:457-462.
19. Shedlock, D. J., Whitmire, J. K., Tan, J., MacDonald, A. S., Ahmed, R. and Shen, H., Role of CD4 T cell help and costimulation in CD8 T cell responses during Listeria monocytogenes infection. J. Immunol. 2003. 170: 2053-2063.
20. Tarte, K. and Klein, B., Dendritic cell-based vaccine: a promising approach for cancer immunotherapy. Leukemia 1999. 13: 653-663.
21. Metheringham, R. L., Pudney, V. A., Gunn, B., Towey, M., Spendlove, I. and Durrant L. G., Antibodies designed as effective cancer vaccines. Mabs-Austin 2009. 1: 71-85.
22. Regnault, A., Lankar, D., Lacabanne, V., Rodriguez, A., Thery, C., Rescigno, M. et al., Fcgamma receptor-mediated induction of dendritic cell maturation and major histocompatibility complex class I-restricted antigen presentation after immune complex internalization. J. Exp. Med. 1999. 189: 371-380.
23. Pudney, V. A., Metheringham, R. L., Gunn, B., Spendlove, I., Ramage, J. M. and Durrant, L. G., DNA vaccination with T-cell epitopes encoded within Ab molecules induces high-avidity anti-tumor CD8+ T cells. Eur. J. Immunol. 2010. 40: 899-910.
24. Brentville, V. A., Metheringham, R. L., Gunn, B. and Durrant, L. G., High avidity cytotoxic T lymphocytes can be selected into the memory pool but they are exquisitely sensitive to functional impairment. PloS One 2012. 7: e41112.
25. Quintarelli, C., Dotti, G., Hasan, S. T., De Angelis, B., Hoyos, V., Errichiello, S. et al., High-avidity cytotoxic T lymphocytes specific for a new PRAME-derived peptide can target leukemic and leukemic-precursor cells. Blood 2011. 117: 3353-3362.
26. Zhu, Z., Singh, V., Watkins, S. K., Bronte, V., Shoe, J. L., Feigenbaum, L., Hurwitz, A. A., High-avidity T cells are preferentially tolerized in the tumor microenvironment. Cancer Res. 2013. 73: 595-604.
27. Weiss, V. L., Lee, T. H., Song, H., Kouo, T. S., Black, C. M., Sgouros, G., Jaffee, E. M. et al., Trafficking of high avidity HER-2/neu-specific T cells into HER-2/neu-expressing tumors after depletion of effector/memory-like regulatory T cells. PloS One 2012. 7: 1-16.
28. Galon, J., Costes, A., Sanchez-Cabo, F., Kirilovsky, A., Mlecnik, B., Lagorce-Pages, C., Tosolini, M. et al., Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 2006; 313: 1960-1964.
29. Ladoire, S., Mignot, G., Dabakuyo, S., Arnould, L., Apetoh, L., Rebe, C., Coudert, B. et al., In situ immune response after neoadjuvant chemotherapy for breast cancer predicts survival. J. Pathol. 2011. 224: 389-400.
30. Mlecnik, B., Tosolini, M., Kirilovsky, A., Berger, A., Bindea, G., Meatchi, T., Bruneval, P. et al., Histopathologic-based prognostic factors of colorectal cancers are associated with the state of the local immune reaction. J. Clin. Oncol. 2011. 29: 610-618.
31. Emens, L. A., Silverstein, S. C., Khleif, S., Marincola, F. M. and Galon, J., Toward integrative cancer immunotherapy: targeting the tumor microenvironment. J. Transl. Med. 2012. 10: 70.